ResMed Stock Price and Value Analysis

ResMed (NYSE:RMD) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold ResMed to reach your target.

Target type

RMD Free Cash Flow Trend

Free Cash Flow trendline for RMD
Free Cash Flow trendline for ResMed
CSV

Based on historical returns, we believe that ResMed can grow its free cash at a rate of about 14%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a great rate!
  • This company has a low dividend yield.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.

Inside the RMD Numbers

RMD Price
(ResMed stock price per share)
$235.63
[?] RMD Fair Price
(based on intrinsic value)
$130.36
[?] RMD Safety Price (based on a variable margin of safety) $78.22
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 6% higher than other Healthcare stocks
[?] PE Ratio versus Industry 185% higher than other Medical Devices stocks
[?] Cash Yield 1.15%
[?] Free Cash Flow Jitter 49%
[?] Dividend Yield 1.04% (tax impact)
Shares Shorted 10,471,435

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 10,471,435 shares shorted. With 139,800,469 shares available for purchase and an average trading volume over the past 10 trading days of 1,190,580, it would take at least 8.8 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 943819 129
2010 943819 105
2011 943819 205
2012 943819 313
2013 943819 334
2014 943819 330
2015 943819 321
2016 943819 487
2017 943819 350
2018 943819 441
2019 943819 396
2020 943819 733
2021 943819 658
2022 943819 258
2023 943819 589
2024 943819 1,291
2025 943819 1,642
2026 943819 1,686

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 18 fiscal years from 2009 to 2026 with positive net income, operating cash flow totaled $11,739 million against net income of $9,957 million, or 1.18 times.

In 2026, operating cash flow was 1.19 times net income, compared with 1.26 times for the earliest three years (2009 to 2011).

In 2026, capital expenditures were $156 million, 8.7% of operating cash flow of $1,806 million, which leaves an estimated $1,650 million after capex. Across the 18 years with reported capex, it averaged 13.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 146 239 110 1.63
2010 190 188 56.9 0.99
2011 227 283 66.6 1.25
2012 255 383 47.1 1.50
2013 307 403 63.6 1.31
2014 345 391 72.7 1.13
2015 353 383 62.5 1.09
2016 352 548 58.5 1.55
2017 342 414 62.2 1.21
2018 316 505 62.6 1.60
2019 405 459 68.7 1.13
2020 622 802 95.3 1.29
2021 475 737 103 1.55
2022 779 351 135 0.45
2023 898 693 120 0.77
2024 1,021 1,401 99.5 1.37
2025 1,401 1,752 89.9 1.25
2026 1,523 1,806 156 1.19

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2017 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $8,045 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $2,496 million, 31.0% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $1,227 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2026, dividends and cash spent repurchasing shares together were $1,050 million, 62.3% of estimated free cash flow of $1,686 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2017 350 186 n/a 186 53.2%
2018 441 199 53.8 253 57.4%
2019 396 212 22.8 235 59.2%
2020 733 225 n/a 225 30.7%
2021 658 227 n/a 227 34.4%
2022 258 245 n/a 245 95.0%
2023 589 258 n/a 258 43.8%
2024 1,291 282 150 432 33.5%
2025 1,642 311 300 611 37.2%
2026 1,686 350 700 1,050 62.3%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $921 million in 2009 and $5,653 million in 2026, a compound annual growth rate of 11.3% over 17 years.

Revenue rose 9.9% from 2025 to 2026.

Our estimated free cash flow was $1,686 million in 2026, 29.8% of revenue. In 2009 the estimated margin was 14.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 921 129 14.0%
2010 1,092 105 9.6%
2011 1,243 205 16.5%
2012 1,369 313 22.9%
2013 1,514 334 22.1%
2014 1,555 330 21.2%
2015 1,679 321 19.1%
2016 1,839 487 26.5%
2017 2,067 350 16.9%
2018 2,340 441 18.9%
2019 2,607 396 15.2%
2020 2,957 733 24.8%
2021 3,197 658 20.6%
2022 3,578 258 7.2%
2023 4,223 589 13.9%
2024 4,685 1,291 27.6%
2025 5,146 1,642 31.9%
2026 5,653 1,686 29.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2026, cash and equivalents were $1,469 million against total liabilities of $2,381 million, or 61.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 26.6% of total assets in 2026, compared with 20.8% in 2010, an increase of 5.7 percentage points.

Stockholders equity was $6,585 million in 2026, compared with $1,288 million in 2010, a rise of 411.5%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 27.6% in 2026. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 1,626 489 339 1,288
2011 2,069 735 338 1,731
2012 2,138 810 530 1,608
2013 2,211 876 600 1,611
2014 2,361 906 603 1,758
2015 2,182 717 594 1,587
2016 3,257 731 1,562 1,695
2017 3,468 822 1,508 1,960
2018 3,064 189 1,005 2,059
2019 4,108 147 2,035 2,072
2020 4,587 463 2,090 2,497
2021 4,728 295 1,842 2,886
2022 5,096 274 1,735 3,361
2023 6,752 228 2,622 4,130
2024 6,872 238 2,008 4,864
2025 8,174 1,209 2,207 5,968
2026 8,966 1,469 2,381 6,585

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $235.63, our model's value equals that price if free cash flow grows an average of 24.8 percent a year over the 10 projection years. Our model assumes 13.6 percent a year for this stock, so the price implies growth of 24.8 percent, which is above the 13.6 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 24.8 percent a year, free cash flow would grow about 9.1 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $384 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $188.50 20.8%
Current price $235.63 24.8%
20 percent above the current price $282.76 27.9%
Our model (stored fair price) $130.36 13.6%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $235.63, the price is above our fair value estimate of $130.36 for ResMed.

Every one of the 18 fiscal years we have for ResMed under its current filer shows positive free cash flow.

The latest three years average $1,540 million in free cash flow against $147 million for the earliest three, which is a sharp rise.

Year-to-year variability in free cash flow is volatile, measured at 49%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

ResMed yields 1.04% in dividends.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 6% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 185% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to ResMed, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
ResMed (RMD) 33,143 21.5 1.0% 1.2% 81% above
DexCom (DXCM) 29,582 31.2 - 0.1% 864% above
West Pharmaceutical Services (WST) 27,189 43.8 0.2% 0.6% 320% above
Baxter International (BAX) 13,135 - 0.2% 11.4% 61% below
Penumbra (PEN) 12,578 80.4 - - 781% above
Globus Medical (GMED) 8,861 16.5 - - 61% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.6% 24% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 943819.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2026
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: RMD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in RMD

Does ResMed have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: RMD

This example shows how we apply the Trendshare checklist to RMD: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 235.63
    • Market cap: $33B
    • EPS: 10.98
  2. Step 2 — Valuation checks

    • P/E: 21.46
    • FCF yield: 1.2%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.